UPDATE: Aldeyra Says Primary Endpoint For TRANQUILITY-2 Trial Modified 'to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022'